Recruiting
Phase 3

Ketamine & Levetiracetam

Sponsor:

University of Virginia

Code:

NCT06907173

Conditions

Status Epilepticus

Eligibility Criteria

Sex: All

Age: 1+

Healthy Volunteers: Not accepted

Interventions

Levetiracetam (LEV) (60 mg/Kg) + 1 mg/kg Ketamine (KET)

Levetiracetam (LEV) (60 mg/Kg) + 3 mg/kg Ketamine (KET)

Levetiracetam (LEV) (60 mg/Kg)

Study Details

Brief summary:

The goal of this clinical trial is to determine if treatment of patients with two doses of ketamine plus levetiracetam versus levetiracetam alone leads to more effective control of status epilepticus.

Conditions

Status Epilepticus

Study ID

NCT06907173

Start date

Mar 6, 2026

Status verified date

Apr, 2026

Completion date

Dec, 2029

Anticipated

Primary completion date

Jun, 2029

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 1+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • The patient was witnessed to have a convulsive seizure for greater than 5-minute duration
  • The patient received an adequate dose of benzodiazepines. The doses may be divided.
  • The last dose of a benzodiazepine was administered 5-30 minutes before study drug administration.
  • Continued or recurring seizures in the Emergency Department.
  • Age 1 years or older
  • Known or estimated weight ≥10 Kg

Exclusion Criteria:

  • Known pregnancy
  • Prisoner
  • Opt-out identification or otherwise known to be previously enrolled in KESETT
  • Treatment with a second line anticonvulsant (FOS, PHT, VPA, LEV, phenobarbital, or other agents defined in the MoP) for this episode of SE
  • Treatment with sedatives with anticonvulsant properties other than benzodiazepines for this episode of SE(propofol, etomidate, ketamine or other agents defined in the MoP)
  • Endotracheal intubation prior to enrollment
  • Acute traumatic brain injury clearly precedes seizures
  • Scalp injury or burn preventing EEG placement
  • Known allergy or other known contraindication to KET or LEV
  • Hypoglycemia < 50 mg/dL
  • Hyperglycemia > 400 mg/dL
  • Cardiac arrest / post-anoxic seizures

Study Design

Enrollment

770 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

active comparator: Levetiracetam

Levetiracetam (LEV) (60 mg/Kg)

experimental: Levetiracetam + low dose Ketamine

LEV 60 mg/mL + 1 mg/mL KET

experimental: Levetiracetam + high dose Ketamine

LEV 60 mg/mL + 3 mg/mL KET increasing up to a weight of 75 kg

Interventions

Levetiracetam (LEV) (60 mg/Kg) + 1 mg/kg Ketamine (KET)

The study drug will be produced at the central pharmacy, a GMP facility at the University of California, Davis. Diluted formulations are expected to remain stable for months when stored at room temperature. Expiration dates for study drugs will be determined and adjusted based on ongoing stability testing performed on study drugs prepared at the GMP facility for the study.

All three formulations will be transparent solutions. None of the formulations are reported to consistently cause adverse effects at the infusion site. The method of drug administration, including volume and rate of infusion, is identical for all three drugs. These factors ensure that drug administration will be blinded.

Levetiracetam (LEV) (60 mg/Kg) + 3 mg/kg Ketamine (KET)

The study drug will be produced at the central pharmacy, a GMP facility at the University of California, Davis. Diluted formulations are expected to remain stable for months when stored at room temperature. Expiration dates for study drugs will be determined and adjusted based on ongoing stability testing performed on study drugs prepared at the GMP facility for the study.

All three formulations will be transparent solutions. None of the formulations are reported to consistently cause adverse effects at the infusion site. The method of drug administration, including volume and rate of infusion, is identical for all three drugs. These factors ensure that drug administration will be blinded.

Levetiracetam (LEV) (60 mg/Kg)

The study drug will be produced at the central pharmacy, a GMP facility at the University of California, Davis. Diluted formulations are expected to remain stable for months when stored at room temperature. Expiration dates for study drugs will be determined and adjusted based on ongoing stability testing performed on study drugs prepared at the GMP facility for the study.

All three formulations will be transparent solutions. None of the formulations are reported to consistently cause adverse effects at the infusion site. The method of drug administration, including volume and rate of infusion, is identical for all three drugs. These factors ensure that drug administration will be blinded.

Primary outcome measure

  • Termination of SE [ Time Frame: From 15 minutes after starting the study drug infusion, sustained for 60 minutes without using additional anti-seizure medication. ]

Central Contacts and Locations

Central contacts

Locations

Banner University Medical Center - Tucson Campus

Recruiting

Tucson, Arizona, United States, 85724

Contacts

Principal Investigator:

Aaron Leetch, MD

Stanford University Medical Center

Recruiting

Palo Alto, California, United States, 94304

Contacts

Alexandra June Gordon, MD

650-248-7701ajgordon@stanford.edu

Principal Investigator:

Alexandra June Gordon, MD

UC Davis Medical Center

Recruiting

Sacramento, California, United States, 95817

Contacts

Principal Investigator:

Daniel Nishijima, MD

San Francisco General Hospital

Recruiting

San Francisco, California, United States, 94143

Contacts

Principal Investigator:

Debbie Madhok, MD

UCSF Medical Center

Recruiting

San Francisco, California, United States, 94143

Contacts

Principal Investigator:

Debbie Madhok, MD

Yale New Haven Hospital

Recruiting

New Haven, Connecticut, United States, 06519

Contacts

Principal Investigator:

Charles Wira, MD

Nemours Children's Hospital

Recruiting

Wilmington, Delaware, United States, 19803

Contacts

Principal Investigator:

Amy Thompson, MD

Children's National Medical Center

Recruiting

Washington D.C., District of Columbia, United States, 20010

Contacts

Principal Investigator:

James Chamberlain, MD

Orlando Regional Medical Center

Recruiting

Orlando, Florida, United States, 32806

Contacts

Principal Investigator:

Dipali Nemade, MD

Arthur M. Blank Hospital

Recruiting

Atlanta, Georgia, United States, 30329

Contacts

Principal Investigator:

Claudia Morris, MD

Rush University Medical Center

Recruiting

Chicago, Illinois, United States, 60612

Contacts

Principal Investigator:

Michael Gottlieb, MD, MBA

Comer Children's Hospital

Recruiting

Chicago, Illinois, United States, 60637

Contacts

Principal Investigator:

David Beiser, MD

University of Chicago Medical Center

Recruiting

Chicago, Illinois, United States, 60637

Contacts

Principal Investigator:

David Beiser, MD

IU Health Methodist Hospital

Recruiting

Indianapolis, Indiana, United States, 46202

Contacts

Principal Investigator:

Daniel Udrea, MD

Riley Hospital for Children

Recruiting

Indianapolis, Indiana, United States, 46202

Contacts

Benjamin Nti, MD

317-416-7997bnti@iu.edu

Principal Investigator:

Benjamin Nti, MD

University of Iowa Medical Center

Recruiting

Iowa City, Iowa, United States, 52242

Contacts

Principal Investigator:

Brett Faine, MD

University of Maryland Medical Center

Recruiting

Baltimore, Maryland, United States, 21201

Contacts

Principal Investigator:

Jennifer Hopp, MD

Johns Hopkins Hospital

Recruiting

Baltimore, Maryland, United States, 21287

Contacts

Kathryn Rosenblatt, MD

410-955-6488krosenb3@jhmi.edu

Principal Investigator:

Kathryn Rosenblatt, MD

University of Michigan University Hospital

Recruiting

Ann Arbor, Michigan, United States, 48109

Contacts

Principal Investigator:

Mariama Runcie, MD

University of Minnesota Masonic Children's Hospital

Recruiting

Minneapolis, Minnesota, United States, 55414

Contacts

Principal Investigator:

James Miner, MD

University of Minnesota Medical Center

Recruiting

Minneapolis, Minnesota, United States, 55455

Contacts

Principal Investigator:

James Miner, MD

University of Cincinnati Medical Center

Recruiting

Cincinnati, Ohio, United States, 45267

Contacts

Principal Investigator:

Jason McMullan, MD

Nationwide Children's Hospital

Recruiting

Columbus, Ohio, United States, 43205

Contacts

Aarti Gaglani Aarti Gaglani, MD

6147226910kesett@nationwidechildrens.org

Principal Investigator:

Aarti Gaglani, MD

OSU Wexner Medical Center

Recruiting

Columbus, Ohio, United States, 43210

Contacts

Principal Investigator:

Kirstin Acus, MD

Oregon Health & Science University Hospital

Recruiting

Portland, Oregon, United States, 97239

Contacts

Principal Investigator:

Bory Kea, MD

Temple University Hospital Jeanes Campus

Recruiting

Philadelphia, Pennsylvania, United States, 19111

Contacts

Principal Investigator:

Derek Isenberg, MD

Temple University Hospital Main Campus

Recruiting

Philadelphia, Pennsylvania, United States, 19140

Contacts

Principal Investigator:

Derek Isenberg, MD

Jefferson Einstein Philadelphia Hospital

Recruiting

Philadelphia, Pennsylvania, United States, 19141

Contacts

Principal Investigator:

Joseph Herres, DO

UPMC Presbyterian Hospital

Recruiting

Pittsburgh, Pennsylvania, United States, 15213

Contacts

Principal Investigator:

Adam Frisch, MD

UPMC Children's Hospital of Pittsburgh

Recruiting

Pittsburgh, Pennsylvania, United States, 15224

Contacts

Principal Investigator:

Robert Hickey, MD

Reading Hospital

Recruiting

West Reading, Pennsylvania, United States, 19611

Contacts

Principal Investigator:

Adam Sigal, MD

Memorial Hermann Texas Medical Center

Recruiting

Houston, Texas, United States, 77030

Contacts

Principal Investigator:

Kayleigh Fischer, MD

University of Virginia Medical Center

Recruiting

Charlottesville, Virginia, United States, 22908

Contacts

Principal Investigator:

Thomas Hartka, MD

Harborview Medical Center

Recruiting

Seattle, Washington, United States, 98104

Contacts

Vasisht Srinivasan, MD

585-730-3843vasishts@uw.edu

Principal Investigator:

Vasisht Srinivasan, MD

Children's Hospital of Wisconsin

Recruiting

Milwaukee, Wisconsin, United States, 53226

Contacts

Principal Investigator:

Keli Coleman, MD

Froedtert Hospital

Recruiting

Milwaukee, Wisconsin, United States, 53226

Contacts

Principal Investigator:

Jamie Jasti, MD

More Information

Sponsor

University of Virginia

Last update posted

Sep 17, 2026

Last verified

Apr, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-10-24. This information was provided to ClinicalTrials.gov by University of Virginia on 2026-09-17. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.